Lake Forest, CA — June 2025 Biodynamik was selected as one of the Top 5 finalists in the American Diabetes Association’s (ADA) 2025 Innovation Challenge, gaining the opportunity to present its mission and breakthrough technology during the ADA’s prestigious scientific competition at the 85th Scientific Sessions.

The Innovation Challenge highlights the most promising startups addressing the critical needs of people living with diabetes and its complications. As a finalist, Biodynamik showcased its automated XT3 System, designed to seamlessly perform the Transverse Tibial Bone Transport (TTT) procedure.

Johnny represented Biodynamik in the competition and shared the company’s vision for transforming diabetic foot care. “Recognition from the American Diabetes Association carries tremendous weight. It affirms that we are addressing a critical and life-threatening problem in diabetes care, and that our solution represents a real step forward for patients who today are faced with limited options.” Chen said.

This recognition marks an important milestone in Biodynamik’s journey, further elevating its visibility in the clinical and scientific community and underscoring the company’s commitment to advancing breakthrough technologies that can redefine outcomes for patients who currently face no treatment options beyond amputation.